Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015’, provides an overview of the Post-Traumatic Stress Disorder (PTSD)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Post-Traumatic Stress Disorder (PTSD) Overview
- Therapeutics Development
- Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview
- Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis
- Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies
- Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes
- Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Unknown Stage Products
- Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies
- Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes
- Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Azevan Pharmaceuticals, Inc.
- Catalyst Pharmaceutical Partners, Inc.
- Eli Lilly and Company
- HolsboerMaschmeyer NeuroChemie GmbH
- Humanetics Corporation
- Intra-Cellular Therapies, Inc.
- Marinus Pharmaceuticals, Inc.
- Neuralstem, Inc.
- Neurocrine Biosciences, Inc.
- NeuroNascent, Inc.
- Omeros Corporation
- Otsuka Holdings Co., Ltd.
- Pfizer Inc.
- Polleo Pharma Limited
- Synchroneuron Inc.
- Tonix Pharmaceuticals Holding Corp.
- Vanda Pharmaceuticals Inc.
- Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- acamprosate calcium SR - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ADX-71743 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AM-3506 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- brexpiprazole - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CPP-115 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug for Post-Traumatic Stress Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drugs to Inhibit FAAH for CNS Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ganaxolone - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HL-9001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IC-87201 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- iloperidone - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ITI-007 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NNI-351 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NSI-189 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PF-04457845 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Rycal - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- S-107 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecule to Target GPR151 for CNS Diseases - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules for Post-Traumatic Stress Disorder - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SRX-246 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TNX-102 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Vaccine for Post-Traumatic Stress Disorder and Depression - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- verucerfont - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- vigabatrin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ZL-006 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Post-Traumatic Stress Disorder (PTSD) - Recent Pipeline Updates
- Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
- Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
- Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
- Featured News & Press Releases
- Aug 18, 2015: Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium
- May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR
- May 15, 2015: Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry
- Jan 15, 2015: Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder
- Jun 10, 2014: Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder
- Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013
- Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome
- Oct 24, 2012: Tonix Pharma Completes Pre-IND Meeting With FDA For Potential New Treatment For Post-Traumatic Stress Disorder
- Oct 15, 2012: Indiana University Scientists Identify New Compound That Could Prevent Post-Traumatic Stress Disorder
- Oct 15, 2012: Indiana University Scientists Discover New Drug For Preventing Post-Traumatic Stress Disorder
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2015
- Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Late Stage Development, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Development, H2 2015
- Comparative Analysis by Unknown Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- Products under Development by Companies, H2 2015 (Contd..1)
- Products under Investigation by Universities/Institutes, H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation, H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neurocrine Biosciences, Inc., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pfizer Inc., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Polleo Pharma Limited, H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Pipeline by Vanda Pharmaceuticals Inc., H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Stage and Target, H2 2015
- Number of Products by Stage and Mechanism of Action, H2 2015
- Number of Products by Stage and Route of Administration, H2 2015
- Number of Products by Stage and Molecule Type, H2 2015
- Post-Traumatic Stress Disorder (PTSD) Therapeutics - Recent Pipeline Updates, H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2015
- Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2015
- List of Figures
- Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2015
- Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Products, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Top 10 Targets, H2 2015
- Number of Products by Stage and Top 10 Targets, H2 2015
- Number of Products by Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
- Number of Products by Top 10 Routes of Administration, H2 2015
- Number of Products by Stage and Top 10 Routes of Administration, H2 2015
- Number of Products by Top 10 Molecule Types, H2 2015
- Number of Products by Stage and Top 10 Molecule Types, H2 2015
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook